660
Participants
Start Date
February 24, 2025
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2028
CS2009
CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
CS2009
CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 14/21-day cycles (Q2W/Q3W).
Pemetrexed
IV infusion
Carboplatin
IV infusion
Paclitaxel
IV infusion
Etoposide
IV infusion
Nab-paclitaxel
IV infusion
Oxaliplatin
IV infusion
Capecitabine
oral tablets
RECRUITING
Alfred Hospital (Alfred Health), Melbourne
RECRUITING
Austin Hospital (Austin Health), Melbourne
RECRUITING
Monash Medical Centre (Monash Health), Melbourne
RECRUITING
Icon Cancer Centre South Brisbane, South Brisbane
RECRUITING
Blacktown Hospital, Sydney
RECRUITING
Macquarie University Hospital, Sydney
RECRUITING
Scientia Clinical Research Ltd, Sydney
RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
Jilin Cancer Hospital, Changchun
NOT_YET_RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Anhui Provincial Hospital, Hefei
RECRUITING
Linyi Cancer Hospital, Linyi
RECRUITING
Shanghai East Hospital, Shanghai
RECRUITING
Shanghai Pulmonary Hospital, Shanghai
RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Xuzhou Central Hospital, Xuzhou
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Lead Sponsor
CStone Pharmaceuticals
INDUSTRY